Bullous lesions at polyethylene glycol interferon-alpha-2a inoculation site in a hepatitis C virus-infected subject

Acta Dermato-Venereologica

Volumn 87, Issue 5, 2007, Pages 433-434

  Montesu, M Antonietta ^a   Siddi, Valentina ^a   Satta, Rosanna ^a   Pirodda, Caterina ^a   Cottoni, Francesca ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; UNCLASSIFIED DRUG;

ADULT; ARM; CASE REPORT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INOCULATION; LETTER; LIVER DISEASE; PRIORITY JOURNAL; SKIN BIOPSY; VESICULAR RASH; BULLOUS SKIN DISEASE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MIDDLE AGED; POLYETHYLENE GLYCOLS; SKIN DISEASES, VESICULOBULLOUS;

EID: 38449088083     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0272     Document Type: Letter

References (10)

1. Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NM, Careddu GF, et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol Interferon. Acta Derm Venereol 2004; 84: 120-123.
2. Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects associated with interferon-alpha therapy: a review. Cutis 1995; 56: 144.
3. Gurguta C, Kauer C, Bergholz U, Formann E, Steindl-Munda P, Ferenci P. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2006; 101: 197-198.
4. Tomasiewicz K, Modrzewska R, Semczuk G. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. Adv Ther 2006; 23: 139-142.
5. Weinberg JM, Wolfe JT, Sood S, Saruk M, Rook AH, Spiers EM. Cutaneous necrosis associated with recombinant interferon. Acta Derm Venereol 1997; 77: 146-148.
6. Sparsa A, Loustaud-Ratti V, Alain S, Liozou E, Bedane C, Vidal E. Skin necrosis after injection of PEG-Interferon α2b in an HCV-infected patient. Acta Derm Venereol 2004; 84: 415-416.
7. Dalmau J, Pimentel CL, Puig L, Peramiquet L, Roé E, Alomar AL. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol 2005; 53: 62-66.
8. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004; 40: 675-681.
9. Kawada K, Maeda N, Kobayashi S, Sowa J, Tsuruta D, Kawada N. Injection site with generalized rash caused by pegylated interferon alpha 2a injection. Dermatology 2006; 212: 82-83.
10. Ruiz de Casas A, Garcia-Bravo B, Camacho F. Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus. Actas Dermosifiliogr 2005; 96: 122-123.